Immune thrombocytopaenic purpura (ITP) is an autoimmune bleeding disease that is rarely fatal. However, in many adults treatment is unsatisfactory, with as much morbidity from the immunosuppressive effects of treatment as from bleeding. Identifying the underlying disease process should help us to identify more targeted therapies and improve not only the treatment but also the quality of life of patients with this disorder.
No takes yet. Share an insight, caveat, or question.
Cooper et al. (2006) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: